The last two decades have seen a surge in antimalarial drug development with product
development partnerships taking a leading role. Resistance of Plasmodium falciparum to the …

Malaria remains one of the most preventable causes of adverse birth outcomes. Intermittent
preventive treatment in pregnancy (IPTp) with sulfadoxine–pyrimethamine is used to prevent …

The deployment of artesunate for severe malaria and the artemisinin combination therapies
(ACTs) for uncomplicated malaria has been a major advance in antimalarial therapeutics …

Background Children who have been hospitalized with severe anemia in areas of Africa in
which malaria is endemic have a high risk of readmission and death within 6 months after …

The emergence and spread of drug resistance in the Greater Mekong Subregion (GMS)
have added urgency to accelerate malaria elimination while reducing the treatment options …

Introduction: Malaria in pregnancy and postpartum cause maternal mortality and adverse
fetal outcomes. Efficacious and safe antimalarials are needed to treat and prevent such …

Young children are the population most severely affected by Plasmodium falciparum
malaria. Seasonal malaria chemoprevention (SMC) with amodiaquine and sulfadoxine …

Introduction Malaria is still a public health problem in Africa. Seasonal Malaria
Chemoprevention (SMC) is an efficient control strategy recommended by WHO that targets …

Abstract Background Dihydroartemisinin-piperaquine (DHA-PQ) is highly efficacious as
intermittent preventive therapy for malaria during pregnancy (IPTp). Determining …

Malaria is an infectious disease which disproportionately effects children and pregnant
women. These vulnerable populations are often excluded from clinical trials resulting in one …